Yarrow Bioscience, Inc. Common Stock
Follow $YARW
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $YARW by emailVeridion Score
BETALOW CONF · 4 of 6 factors measuredHighest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is YARW moving today?
Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
YARW overview
Related filings and maps
Congress activity in YARW
No receipt-qualified Congressional disclosure is present for YARW in the cached public ledger.
YARW contract awards, year to date.
Public federal awards linked to this ticker.
YARW lobbying filings, year to date.
Registered lobbying filings matched to Yarrow Bioscience, Inc. Common Stock.